Physician profile
Robert S Larimer
NPI 1023052024
$1,798.48
in general payments reported to CMS, 2019-2025
21 companies · $698 in 2025
The $698 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.18 · 2020: $29.18 · 2021: $375 · 2022: $144 · 2023: $256 · 2024: $238 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,191.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $250.00 | 2021 | |
| Vanda Pharmaceuticals INC. | $242.40 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $194.16 | 2024-2025 | Uzedy, Austedo Xr |
| Ardelyx, INC. | $177.45 | 2024-2025 | Ibsrela |
| Ucb, INC. | $167.42 | 2022-2025 | Fintepla, Briviact, Nayzilam |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Lilly USA, LLC | $113.85 | 2019-2023 | Mounjaro |
| Sk Life Science, INC. | $94.14 | 2022-2024 | Xcopri |
| Sumitomo Pharma America, INC. | $89.50 | 2023-2024 | Aptiom |
| Neurelis, INC. | $74.15 | 2023-2025 | Valtoco |
| Janssen Pharmaceuticals, INC | $43.80 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $43.28 | 2023-2025 | Daybue |
| Jazz Pharmaceuticals INC. | $30.95 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $30.52 | 2022 | |
| Neurocrine Biosciences, INC. | $28.99 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $16.87 | 2024 | Palynziq |
| Immedica Pharma US, INC. | $16.39 | 2023 | |
| Eusa Pharma (US) LLC | $16.29 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.24 | 2025 | Rexulti |
| Eisai INC. | $14.42 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $13.66 | 2025 | Kristalose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Larimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.